Osteosarcoma is the most common non-hematologic primary malignant neoplasm of the bone and the disease is mainly developed in young patients between 10 and 25 years old. Early detection and differentiation of osteosarcoma from osteoid osteoma, aneurysmal bone cyst, infectious or inflammatory processes would be of great help for better control of this malignant disease. In this study, we performed in vitro peptidic phage screening and identified a new 12-mer peptide (OSP-1) with high binding affinity to osteosarcoma cells. Conclusions: Our data suggest that OSP-1 peptide is osteosarcoma specific, and the binding site of OSP-1 might be related to heparan sulfate proteoglycans. Appropriately labeled OSP-1 peptide has the potential to serve as a novel probe for osteosarcoma imaging.
INTRODUCTION
Osteosarcoma, the most common non-hematologic primary malignant neoplasm of the bone, is characterized by the development of bone or osteoid substance by the tumor cells (1) .
The disease is mainly developed in young patients between 10 and 25 years old and it is one of the most frequent causes of cancer-related deaths in childhood (2) . Approximately 25% of osteosarcoma metastasize, typically to the lung. Despite effective surgical removal of the primary tumor and aggressive chemotherapy, the rate of long-term survival is only 15% to 20% because of pulmonary metastases, non-responsiveness to therapy or disease relapse (3) .
Clinically, patients with osteosarcoma are usually diagnosed by a palpable mass on physical examination and a characteristic radiographic lesion. Laboratory work can disclose elevations in alkaline phosphatase (ALK), lactate dehydrogenase (LDH), and erythrocyte sedimentation rate (ESR) (4) . However, early detection and differentiation of osteosarcoma from osteoid osteoma, aneurysmal bone cyst, infectious or inflammatory processes would be of great help for better control of this malignant disease.
Compared with traditional methods, molecular imaging usually exploits specific molecular probes as well as intrinsic tissue characteristics as the source of image contrast, and provides the potential for understanding integrative biology, earlier detection and characterization of disease, and evaluation of treatment (5) . Imaging probes with high affinity and specificity would be the key to successful molecular imaging. Phage display technology represents a high-throughput combinatorial technique for screening billions of random fusion peptide ligands against multiple targets on the surface, or located within cancer cells and targets on tumor blood vessels (6) . The distinctive advantage of this technique is that targets may be unknown and non-immunogenic yet may serve as a delineating character for a particular cell type or tumor type (7) . Meanwhile, these peptide ligands can be conjugated with imaging agents or therapeutic drugs and may be a promising tool for affinity-based targeted delivery of imaging agents and drugs (8) . For example, RGD peptide has been screened with phage display to target integrin proteins (9) . RGD peptide and its derivatives have been widely applied to image integrin expression and tumor angiogenesis after being labeled with various radioisotopes (10) . So far, no specific probe has been developed to image osteosarcoma.
In this study, we performed in vitro peptidic phage screening using human osteosarcoma 143B cells as selecting target with the protocol (Supplemental Figure 1) The peptide OSP-1 and its scrambled peptide OSP-S (DLPSRTSALASG) were synthesized using a peptide synthesizer and purified with HPLC. For peptide labeling, OSP-1 (or OSP-S, 0.5 mg, 0.4 µmol) and DIPEA (7.5 µl) was added to a solution of Cy5.5 NHS ester (0.5 mg, 0.4 µmol) in DMF (150 µl) , the reaction mixture was stirred at room temperature for 2 h and quenched with 10 µl of acetic acid. The crude product was purified by reserve phase HPLC on a semipreparative C-18 column. The desired fractions containing Cy5.5-OSP-1 (or Cy5.5-OSP-S) were collected and lyophilized to give a green fluffy powder. Yield: 57% (> 99% purity solution containing 0.25 mg/mL FITC. The phage/fluorochrome reaction was allowed to continue for 1 hour at room temperature in the dark. Subsequent to incubation, the volume of the labeled OSP-1-phage was brought up to 1 ml with DPBS, and the OSP-1-phage was then PEGprecipitated twice and dialyzed extensively against 50 mM Tris-HCl and 150 mM NaCl (pH 7.5; TBS) to remove excess FITC (12) .
Fluorescence staining
Research. The cell uptake studies were performed as we have previously described with some modifications (14) . Briefly, 143B, UM-SCC1 or 293T cells were seeded into 12-well plates at a density of 5×10 
MicroPET imaging
PET scans and image analysis were performed using an Inveon microPET scanner (Siemens Medical Solutions). Each 143B and UM-SCC1 tumor-bearing mouse was injected in a tail vein 
Ex vivo biodistribution
Female athymic nude mice bearing 143B and UM-SCC1 xenografts were injected with 
Statistical analysis
Quantitative data were expressed as means±SD. Means were compared using one-way analysis of variance (ANOVA) and a Student's t test. P values <0.05 were considered statistically significant.
RESULTS

Identification of 143B-binding peptide OSP-1
Four selection rounds were performed on the 143B cell line with a linear 12-amino-acid peptide library to allow for enrichment of tumor cell binding or internalizing phages. Before each selection round, a negative selection with the 293T human embryonic kidney cell line was performed to subtract phages that bound to non-tumor cells. After the final selection round, . We then checked HSPG receptor specificity of OSP-1 peptide. As shown in Figure   3B , pre-incubation with OSP-1 peptide abrogated the binding of heparin/heparan sulfate antibody to 143B osteosarcoma cells.
Cell uptake and efflux of OSP-1
We further developed OSP-1 as a PET imaging tracer by labeling it with a positron emitting radioisotope, 
MicroPET imaging
Next, we performed in vivo microPET imaging with 
Biodistribution studies
Research. 
